The differences between tenofovir and propofol tenofovir are characterized by structural properties, indications, adverse effects, and protein binding. 1. Structural properties (1) Tenofovir: a nucleotide analog. (2) Propofol Tenofovir: a new type of nucleotide analog reverse transcriptase inhibitor. 2. Indications (1) Tenofovir: Treatment of adults with chronic hepatitis B and pediatric patients ≥12 years of age, in combination with other anti-retroviral drugs, for the treatment of HIV-1 infection in adults. (2) Propofol Tenofovir: suitable for the treatment of chronic hepatitis B in adults and adolescents (age 12 years and older, weight 35 kg or more). 3. Adverse reactions (1) Tenofovir: Prolonged oral administration may cause accumulation in the renal tubules to the extent of impairing kidney function. (2) Propofol tenofovir: renal adverse reactions are rare; more common adverse reactions are headache, nausea, and fatigue. 4. Protein binding (1) Tenofovir: the binding rate to human plasma protein is less than 70%. (2) Propofol tenofovir: the binding rate to human plasma proteins is about 80%. The two drugs are different in many ways. If you need to use the drug, please take it correctly under the guidance of a professional doctor, and do not use the drug by yourself to prevent adverse effects.